Oxytrol For Women Draft Questions
This article was originally published in The Tan Sheet
Executive Summary
FDA’s draft questions to the NDAC on Merck’s ’s proposed Rx-to-OTC switch of Oxytrol for Women includes one item to vote on – whether consumers can appropriately self-select the product OTC – while also asking for discussion on possible concerns about safety and about the data included in the firm’s NDA.